» Articles » PMID: 38786726

Metabolic Roles of HIF1, C-Myc, and P53 in Glioma Cells

Abstract

The metabolic reprogramming that promotes tumorigenesis in glioblastoma is induced by dynamic alterations in the hypoxic tumor microenvironment, as well as in transcriptional and signaling networks, which result in changes in global genetic expression. The signaling pathways PI3K/AKT/mTOR and RAS/RAF/MEK/ERK stimulate cell metabolism, either directly or indirectly, by modulating the transcriptional factors p53, HIF1, and c-Myc. The overexpression of HIF1 and c-Myc, master regulators of cellular metabolism, is a key contributor to the synthesis of bioenergetic molecules that mediate glioma cell transformation, proliferation, survival, migration, and invasion by modifying the transcription levels of key gene groups involved in metabolism. Meanwhile, the tumor-suppressing protein p53, which negatively regulates HIF1 and c-Myc, is often lost in glioblastoma. Alterations in this triad of transcriptional factors induce a metabolic shift in glioma cells that allows them to adapt and survive changes such as mutations, hypoxia, acidosis, the presence of reactive oxygen species, and nutrient deprivation, by modulating the activity and expression of signaling molecules, enzymes, metabolites, transporters, and regulators involved in glycolysis and glutamine metabolism, the pentose phosphate cycle, the tricarboxylic acid cycle, and oxidative phosphorylation, as well as the synthesis and degradation of fatty acids and nucleic acids. This review summarizes our current knowledge on the role of HIF1, c-Myc, and p53 in the genic regulatory network for metabolism in glioma cells, as well as potential therapeutic inhibitors of these factors.

Citing Articles

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.

DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.

PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.


The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.

Krawczyk A, Sladowska G, Strzalka-Mrozik B Cancers (Basel). 2025; 17(5).

PMID: 40075568 PMC: 11899293. DOI: 10.3390/cancers17050719.


The role of acetylation and deacetylation in cancer metabolism.

Wang C, Ma X Clin Transl Med. 2025; 15(1):e70145.

PMID: 39778006 PMC: 11706801. DOI: 10.1002/ctm2.70145.


Apoptotic effect of thymoquinone on OVCAR3 cells via the P53 and CASP3 activation.

Karaosmanoglu O, Kamalak Z, Ozdemir I, Ozturk S, Tuncer M Acta Cir Bras. 2024; 39:e399224.

PMID: 39536185 PMC: 11548134. DOI: 10.1590/acb399224.


Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets.

Cortes Ballen A, Amosu M, Ravinder S, Chan J, Derin E, Slika H Cells. 2024; 13(18.

PMID: 39329757 PMC: 11430559. DOI: 10.3390/cells13181574.


References
1.
Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S . Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017; 8(1):1823. PMC: 5703960. DOI: 10.1038/s41467-017-01947-w. View

2.
Schofield C, Zhang Z . Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol. 1999; 9(6):722-31. DOI: 10.1016/s0959-440x(99)00036-6. View

3.
Her N, Oh J, Oh Y, Han S, Cho H, Lee Y . Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 2018; 9(8):792. PMC: 6052082. DOI: 10.1038/s41419-018-0825-1. View

4.
Albihn A, Johnsen J, Henriksson M . MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107:163-224. DOI: 10.1016/S0065-230X(10)07006-5. View

5.
Cheng C, Huang L, Chang Y, Hsieh C, Huang S, Hueng D . The mechanisms of malic enzyme 2 in the tumorigenesis of human gliomas. Oncotarget. 2016; 7(27):41460-41472. PMC: 5173072. DOI: 10.18632/oncotarget.9190. View